Menu Search
Equities

Evaxion Biotech A/S

EVAX:NAQ

Evaxion Biotech A/S

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.15
  • Today's Change0.03 / 0.96%
  • Shares traded71.03k
  • 1 Year change-34.38%
  • Beta-0.2559
Data delayed at least 15 minutes, as of Sep 19 2024 20:30 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Cash flow in USDView more

In 2023, cash reserves at Evaxion Biotech A/S fell by 7.60m. Cash Flow from Financing totalled 10.69m or 14,645.21% of revenues. In addition the company used 17.69m for operations while cash used for investing totalled 93.00k.
Cash flow per share--
Price/Cash flow per share--
Book value per share0.2316
Tangible book value per share0.2316
More ▼

Balance sheet in USDView more

Evaxion Biotech A/S has a Debt to Total Capital ratio of 89.33%, a lower figure than the previous year's 395.35%.
Current ratio2.80
Quick ratio--
Total debt/total equity8.37
Total debt/total capital0.8933
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.